Your browser doesn't support javascript.
loading
Treatment of Isoniazid-Resistant Pulmonary Tuberculosis / 결핵
Tuberculosis and Respiratory Diseases ; : 20-30, 2020.
Article in English | WPRIM | ID: wpr-782225
ABSTRACT
Tuberculosis (TB) remains a threat to public health and is the leading cause of death globally. Isoniazid (INH) is an important first-line agent for the treatment of TB considering its early bactericidal activity. Resistance to INH is now the most common type of resistance. Resistance to INH reduces the probability of treatment success and increases the risk of acquiring resistance to other first-line drugs such as rifampicin (RIF), thereby increasing the risk of multidrug-resistant-TB. Studies in the 1970s and 1980s showed high success rates for INH-resistant TB cases receiving regimens comprised of first-line drugs. However, recent data have indicated that INH-resistant TB patients treated with only first-line drugs have poor outcomes. Fortunately, based on recent systematic meta-analyses, the World Health Organization published consolidated guidelines on drug-resistant TB in 2019. Their key recommendations are treatment with RIF-ethambutol (EMB)-pyrazinamide (PZA)-levofloxacin (LFX) for 6 months and no addition of injectable agents to the treatment regimen. The guidelines also emphasize the importance of excluding resistance to RIF before starting RIF-EMB-PZA-LFX regimen. Additionally, when the diagnosis of INH-resistant TB is confirmed long after starting the first-line TB treatment, the clinician must decide whether to start a 6-month course of RIF-EMB-PZA-LFX based on the patient's condition. However, these recommendations are based on observational studies, not randomized controlled trials, and are thus conditional and based on low certainty of the effect estimates. Therefore, further work is needed to optimize the treatment of INH-resistant TB.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Rifampin / Tuberculosis / Tuberculosis, Pulmonary / World Health Organization / Public Health / Cause of Death / Diagnosis / Isoniazid Type of study: Controlled clinical trial / Diagnostic study / Practice guideline / Observational study Limits: Humans Language: English Journal: Tuberculosis and Respiratory Diseases Year: 2020 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Rifampin / Tuberculosis / Tuberculosis, Pulmonary / World Health Organization / Public Health / Cause of Death / Diagnosis / Isoniazid Type of study: Controlled clinical trial / Diagnostic study / Practice guideline / Observational study Limits: Humans Language: English Journal: Tuberculosis and Respiratory Diseases Year: 2020 Type: Article